Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glyceraldehyde-3-phosphate dehydrogenase from Leishmania mexicana (GAPDH (from Leishmania mexicana))
- Target
- GAPDH (from Leishmania mexicana)
- Molecular classification
- Enzyme (Oxidoreductase), Glycolytic enzyme, Glycosomal protein
01
Overview
Glyceraldehyde-3-phosphate dehydrogenase from Leishmania mexicana (LmGAPDH) is a glycolytic oxidoreductase localized predominantly within glycosomes, catalyzing a key step in parasite energy metabolism by converting glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate with NAD+ reduction[1][2][6]. Its structural differences from the human homolog, particularly in substrate/cofactor binding regions and active-site loop conformations, make it a prime target for anti-leishmanial drug development[1][3][4][6][8]. Inhibitors designed to selectively bind these parasite-enzyme features can block glycolysis, suppressing parasite viability and growth. Its activity is essential for Leishmania species survival and pathogenicity, particularly in energy-demanding stages of infection[5][6].
- Other names
- GAPDH (Leishmania mexicana)Glycosomal glyceraldehyde-3-phosphate dehydrogenase (Leishmania mexicana)LmGAPDH
02
Mechanism of action
Competitive or non-competitive inhibition of active site or cofactor binding site, blocking GAPDH enzymatic activity and inhibiting glycolysis in parasite
03
Biological functions
Glycolysis: catalyzes the sixth step, converting glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate with NAD+ reductionEnergy production in parasite metabolismRegulation of glycolytic pathway flux
04
Disease associations
Infection (Leishmaniasis, a protozoan disease)Parasite survival, pathogenicityPotential role in drug resistance due to structural uniqueness
05
Safety considerations
Structural similarities to human GAPDH necessitate selectivity to avoid toxicityRisk of off-target effects if inhibitors are not sufficiently selective
06
Interacting drugs
Adenosine analogs with substitutions on N-6 adenine and 2′ ribose (designed inhibitors targeting LmGAPDH)
1 more in the full profile.
07
Biomarkers
LmGAPDH expression/activity (potential biomarker for parasite presence and response to glycolytic inhibitors)
Beyond the preview
Go deeper on Glyceraldehyde-3-phosphate dehydrogenase from Leishmania mexicana (GAPDH (from Leishmania mexicana)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glyceraldehyde-3-phosphate dehydrogenase from Leishmania mexicana (GAPDH (from Leishmania mexicana)).